RecruitingPHASE2, PHASE3NCT07160205

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Studying Dermatomyositis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Restem, LLC.
Principal Investigator
Michael Bubb, MD
Malcom Randall North Florida/South Georgia VA Medical Center
Intervention
ULSC (1.5 x 10^8 cells/dose)(biological)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
2026 – 2029

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07160205 on ClinicalTrials.gov

Other trials for Dermatomyositis

Additional recruiting or active studies for the same condition.

See all trials for Dermatomyositis →

← Back to all trials